Organon & Co. (OGN) financial statements and ratios from SEC XBRL: revenue $6.1B (TTM), net margin 3.0%, revenue growth -2.3% YoY, P/E 17.3. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $6.22B |
| Revenue (TTM) | $6.1B |
| Net Margin | 3.0% |
| Operating Margin (TTM) | 8.0% |
| Net Debt / EBITDA | 10.8 |
| Revenue Growth (YoY) | -2.3% |
| EPS Growth (YoY) | -26.8% |
| FCF Growth (YoY) | -64.1% |
| P/E Ratio | 17.3 |
| EV / EBITDA | 17.0 |
| Price / Book | 3.59 |
| Price / Sales | 0.59 |
| FCF Yield | 15.7% |
| Altman Z-Score | 1.07 (distress) |
| Piotroski F-Score | 5/9 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
OGN overview · OGN earnings · OGN KPIs · OGN documents · OGN ownership · OGN peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.